New-Tech Magazine Europe | Dec 2015 Digital edition

LVivo SG

LVivo EF

with the conventional evaluation method, which use manually-selected still images as the basis for calculation. The ease and speed of DiACardio’s tools also make it practical to carry out short-cycle, repeatable measurements of patients associated with the risk of the cardiotoxicity effect that may be caused by chemotherapy. DiAcardio’s tools are able to analyze patient data online within the echo unit and/or offline on the PACS’s DICOM video file, taking into account the dynamic nature of the heart. DiAcardio technologies are protected by patents (currently at the national phase). Road map Our target customers are Ultrasound manufacturers, Healthcare IT (PACS) companies and other medical imaging software companies. We sell our software tools on an OEM basis as an integrated plug-in solution. R&D Road map -During 2016 we intend to finish the development of additional 4 cardiac automated tools, obtain FDA/CE for LVivo SG and publish academic articles. M&S road map– we intend to increase

dramatically the marketing and sales of LVivo platform and detect potential partners for our current and upcoming tools. Financial round map - until the end of the first half of 2016 we intend to close an A Round of investment of $5M-$10M that will allows us to expend our technology to other medical imaging platforms and application Awards DiaCardio won 1st place at the ICI innovation awards, just few months after winning 1st place at GIA2015 in China. DiACardio, a Software company, revolutionizes the practice of evaluating “Ultrasound of the heart” (“Echocardiography”), by evaluating the heart performance automatically, at the click of a mouse, in just a few seconds. DiaCardio’s software can easily integrated into any ultrasound unit and healthcare IT (PACS) system. The software is FDA cleared and CE approved and initial sales have been obtained. Co- founders, Hila Goldman-Aslan, the company’s CEO and Co-Founder and

Dr. Noah Liel-Cohen M.D., Head of the Echocardiography Unit at Soroka University Medical Center in Beer- Sheva , presented DiaCardio. The ICI is a global innovation in cardiology conference held for the 20th time. This time a specific focus was on revolution of digital/mobile health technologies. Each year more than 70 applications from 22 countries around the world send their application. Only 10 selected companies are invited to present. DiACardio was evaluated by expert panel judges based of 3principal criteria: the impact on patient care, the impact on novelty and business potential. “Winning this awards is a recognition from the cardiology community of our ground-breaking technology that we have developed at DiACardio” said Hila Goldman-Aslan, the company’s CEO and Co-Founder. Part of wining, DiACardio also gets the chance to present at Europe’s largest cardiovascular conference - EuroPCR 2016 (Paris).

61 l New-Tech Magazine Europe